Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5–11 Years of Age, Israel

We assessed effectiveness of the BNT162b2 vaccine against infection with the B.1.1.529 (Omicron) variant (mostly BA.1 subvariant), among children 5–11 years of age in Israel. Using a matched case–control design, we matched SARS-CoV-2–positive children (cases) and SARS-CoV-2–negative children (contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Glatman-Freedman, Aharona, Hershkovitz, Yael, Dichtiar, Rita, Rosenberg, Alina, Keinan-Boker, Lital, Bromberg, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045694/
https://www.ncbi.nlm.nih.gov/pubmed/36863005
http://dx.doi.org/10.3201/eid2904.221285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045694/
https://www.ncbi.nlm.nih.gov/pubmed/36863005
http://dx.doi.org/10.3201/eid2904.221285

Ejemplares similares